文献速递白血病

妊娠期慢性髓性白血病的管理

How I manage chronic myeloid leukemia during pregnancy.
PubMed 文献 · Blood · 2026-01-01

本文以临床病例为例,探讨妊娠期慢性髓性白血病(CML)的管理,包括酪氨酸激酶抑制剂(TKI)停药时机、无治疗缓解的可行性、干扰素α等替代治疗的作用,以及妊娠中晚期重启治疗、TKI选择和产后管理(含哺乳)等问题。

要点

  • 因TKI有致畸潜力,妊娠早期禁用,确认妊娠后须立即停用TKI。
  • 妊娠前需仔细规划,并考虑干扰素α等替代治疗策略。
  • 需关注妊娠期重启治疗、后续孕期TKI选择及产后哺乳等问题。

核心结论

  • 妊娠期CML管理需在疾病控制与胎儿安全之间取得平衡,通过病例分析为优化母婴结局提供实践指导。

研究设计与样本

  • 本文为综述,采用 illustrative 临床病例探讨妊娠期CML管理的多个方面。

主要发现

  • TKI因致畸潜力在妊娠早期禁用,确认妊娠后须立即停药。
  • 需进行仔细的妊娠前规划并采用替代管理策略。
  • 探讨了TKI停药时机和无治疗缓解的可行性。
  • 讨论了干扰素α等替代治疗的作用。
  • 涉及妊娠期重启治疗的挑战、后续孕期TKI选择及产后管理(含哺乳考虑)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chronic myeloid leukemia (CML) represents a paradigm of success in targeted therapy, with tyrosine kinase inhibitors (TKIs) revolutionizing patient outcomes. This progress has extended to the management of pregnancy in women with CML, a complex scenario requiring a balance between disease control and fetal safety. Because TKIs are contraindicated during the first trimester due to their teratogenic potential, treatment must be stopped as soon as pregnancy is confirmed, necessitating careful preconception planning and alternative management strategies. This article uses illustrative clinical cases to explore key aspects of CML pregnancy management, including the timing of TKI discontinuation, the feasibility of treatment-free remission, and the role of alternative therapies such as interferon alfa. Additionally, we discuss the challenges of restarting treatment during pregnancy, the TKI selection in subsequent trimesters, and postpartum disease management, including breastfeeding considerations. Through the analysis of real-world cases, we provide insights into the evolving landscape of CML and pregnancy, offering practical guidance on optimizing maternal and fetal outcomes in this unique setting.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Abruzzese E, Chelysheva E. How I manage chronic myeloid leukemia during pregnancy. Blood. 2026. PMID: 40758938. doi:10.1182/blood.2024026513

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。